Renibus Therapeutics
Business Services · Texas, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
181 Grand Ave Ste 225, Southlake, Texas,...Phone Number
(682) 285-1711Website
www.renibus.comRevenue
$18.3 MillionIndustry
About Renibus Therapeutics
Renibus Therapeutics was found in 2016 and it is a clinical-stage biotech company dedicated to transforming the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company's portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 for treatment of iron deficiency anemia and platinum-based kidney toxicity.Explore more
Renibus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Renibus Therapeutics
Compare insights from companies similar to Renibus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Renibus Therapeutics
$18.3M
201-500
Private
$250.9M
2016
JK
Jeff KeyserPresident and CEO Renibus Therapeutics
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Renibus Therapeutics Tech Stack
A closer look at the technologies used by Renibus Therapeutics
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Renibus Therapeutics
Sign Up For FreeTo access detailed company insights
Renibus Therapeutics was found in 2016 and it is a clinical-stage biotech company dedicated to transforming the cardiorenal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company's portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, and RBT-3 f... Read More
